cMyc Cancer Research Results

cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
1426- Bos,  CUR,  Chemo,    Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer
- in-vivo, CRC, NA - in-vitro, CRC, HCT116 - in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vitro, RCC, SW-620 - in-vitro, RCC, HT-29 - in-vitro, CRC, Caco-2
miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1/CCND1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
1182- MushCha,    Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29 - in-vitro, CRC, SW-620 - in-vitro, CRC, DLD1
Apoptosis↑, TumCG↓, FASN↓, β-catenin/ZEB1↓, cMyc↓, cycD1/CCND1↓, CDK8↓, Ki-67↓,
5222- TQ,    Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB
- in-vitro, CRC, COLO205 - in-vitro, CRC, HCT116
tumCV↓, ChemoSen↑, p‑p65↓, NF-kB↓, VEGF↓, cMyc↓, Bcl-2↓, ROS↑,
3413- TQ,    Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase
- in-vitro, CRC, HCT116
tumCV↓, Apoptosis↓, BAX↑, Bcl-2↓, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, EGFR↓, ROS↑,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 2,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 7,   FASN↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 3,   BAX↑, 3,   Bcl-2↓, 3,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp3↑, 2,   Casp7↑, 2,   Casp9↑, 2,   IAP1↓, 1,   JNK↑, 1,   p27↑, 2,   p38↑, 1,   survivin↓, 3,  

Transcription & Epigenetics ⓘ

miR-27a-3p↓, 2,   tumCV↓, 2,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 2,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 6,   P21↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   CDK8↓, 1,   CSCs↓, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   GSK‐3β↓, 1,   Let-7↑, 1,   LGR5↓, 1,   miR-34a↑, 2,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 1,   STAT3↓, 2,   TumCG↓, 4,  

Migration ⓘ

5LO↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   Ki-67↓, 1,   miR-200b↑, 1,   MMP9↓, 1,   MMPs↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   EGFR↓, 1,   VEGF↓, 3,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   NF-kB↓, 2,   p‑NF-kB↑, 1,   p‑p65↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 3,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   TumVol↓, 1,  
Total Targets: 70

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSTA1↑, 1,   SOD↑, 1,  

Migration ⓘ

MMP13↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   Inflam↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,  
Total Targets: 13

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
3 Thymoquinone
2 Boswellia (frankincense)
2 Curcumin
1 Chemotherapy
1 Mushroom Chaga
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:35  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page